F. Deodato

Sticholysin II Identifies Intracellular Lipid Deposits in Niemann Pick C Fibroblasts

G. D’Arcangelo, R. Carrozzo, S. Rufini, 2016 .

An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD)

M. Andreucci, G. Fuiano, L. Abenavoli, 2018, European Journal of Nutrition.

GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings.

E. Bertini, C. Tifft, A. D’Amico, 2011, Biochimica et biophysica acta.

Autosomic dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease

D. Bolignano, G. Coppolino, E. Russo, 2021, Medicinal research reviews.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

A single-residue mutation, G203E, causes 3-hydroxy-3-methylglutaric aciduria by occluding the substrate channel in the 3D structural model of HMG-CoA lyase

R. Aledo, B. Puisac, P. Gómez-Puertas, 2006, Journal of Inherited Metabolic Disease.

Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis

E. Clementi, C. Dionisi-Vici, F. Stoppa, 2016, European Journal of Clinical Pharmacology.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.